Date: 2014-12-18
Type of information: Collaboration agreement
Compound: drug-like screening compounds
Company: Enamine (Ukraine) Sanofi (France)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On December 18, 2014, Enamine, a provider of screening compounds, chemical building blocks and discovery services, has announced that it has extended its collaboration agreement with Sanofi. Based on the success of the collaboration to date, the extension enables Sanofi to continue to access Enamine’s in-house designed and synthesized screening compound library, and select a library subset of novel drug-like screening compounds, according to Sanofi’s research needs. Enamine’s library, which is now the industry’s most extensive range with 2,000,000 compounds, provides Sanofi with an optimal starting point for hit finding activities for multiple therapeutic targets and will be used at Sanofi’s worldwide screening facilities.Michael Bossert, Head of Strategic Alliances at Enamine, commented: “We have worked with Sanofi since 2012 and are delighted to continue our agreement. At Enamine our focus is on the development of original and unique chemistry, and this extension reflects our scientific knowledge and ability to exceed partner expectations. The collaboration involves regular communication with Sanofi teams and is focused on facilitating the creation of new research projects to support the emergence of effective treatments for diseases.”
Financial terms:
Latest news:
